Multicenter, Open-label, Exploratory Clinical Trial With Rhodiola Rosea Extract In Patients Suffering From Burnout Symptoms
Notes for this study:
||Numerical analogue scale: impairment of sexual life. before 6.8±1.5, after 4.2±3.1. Ability to become sexually aroused, before 2.9±1.4, after 3.4±1.2. Ability to have orgasm (PSFQ). Before 3.0±1.3, after 3.3±1.2. Overall satisfication with sexual life: before 2.5±1.1, after 3.2±1.2 . Erections: before 3.2±0.9, after 3.6±0.9.
|Number of Subjects
In a single-arm, open-label trial, 118 participants experiencing burnout were given 400 mg of Rhodiola extract (1.5–5:1, 60% dry ethanolic extract)daily for 12 weeks.
Funding issues for this study:
58% complete the trial. On the Maslach Burnout Inventory, there was a statistically significant improvement in depersonalization, emotional exhaustion, but not involvement or personal accomplishment. On the perceived stress questionnaire, there was a statistically significant reduction in total score, fatigue, harassment, irritability, lack of joy, overload, tension, and worries. The total score on the Burnout Screening Scale was significantly reduced after one week and continued to improve at 8 and 12 weeks. Impairment of sex life and sexual function were generally significantly improved, as were alertness, calmness, and mood.
"Siegfried Kasper has received grant/research support, consulting fees, and/or honoraria within the last 3 years from Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe, and Servier. Dr Dienel is an employee of Dr Willmar Schwabe GmbH & Co. KG."